Asthma, Corticosteroid
Conditions
Brief summary
The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.
Detailed description
South Korea has a compulsory universal health insurance system for entire Korean population. The number of people who are covered was more than 50 million. The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators have performed many studies regarding asthma in South Korea. In this study, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database. Primary outcome was the OCS prescription in all patients with asthma. Secondary outcome was OCS prescription according to the asthma severity, age, sex, socioeconomic status and the type of hospital. Inclusion criteria was 1) Age ≥ 15 years; 2) ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis; 3) use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).
Interventions
The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
Sponsors
Seoul St. Mary's Hospital
Hallym University Medical Center
Konkuk University Hospital
Joon Young Choi
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 15 years; * ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis * use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).
Exclusion criteria
• Those who are not in the insurance system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OCS prescription rates | 1-year | Analysis the OCS prescription in all patients with asthma |
Secondary
| Measure | Time frame |
|---|---|
| OCS prescription according to the asthma severity | 1-year |
| OCS prescription according to age | 1-year |
| OCS prescription according to sex | 1-year |
| OCS prescription according to socioeconomic status | 1-year |
| OCS prescription according to the type of hospital | 1-year |
Countries
South Korea
Contacts
Primary ContactJoon Young Choi, MD.PhD
Outcome results
None listed